Tempus AI Inc

Latest Results (15.05.2026):

Tempus AI Inc — Fourth quarter 2025: Tempus reported strong top-line growth in Q4 2025 with revenue of $367.2 million (up 83.0% year‑over‑year), continued margin expansion and a positive Adjusted EBITDA for the quarter, while GAAP net loss remained due largely to stock‑based compensation. The company exited 2025 with a strengthened contract backlog and guidance for accelerated profitability in 2026.

Revenue and growth (Q4 2025)

Q4 2025 revenue was $367.2M, an 83.0% increase year‑over‑year (full‑year 2025 revenue $1.27B, +83.4% y/y). Management cited organic growth of 33.5% in the quarter excluding Ambry.

Diagnostics performance (Q4 2025)

Diagnostics revenue was $266.9M in Q4 (+121.6% y/y). Volume gains drove growth: Oncology test volume +29% y/y and Hereditary volume +23% y/y; MRD volume was ~4,700 tests in Q4 (up ~56% q/q).

Data & Applications (Q4 2025)

Data and Applications revenue was $100.4M in Q4 (+25.1% y/y). Insights (data licensing) showed strong expansion, up 69.5% y/y when excluding the AstraZeneca warrant impact in Q4 2024. Full‑year Data & Applications was $316.4M (+30.9% y/y).

Profitability and margins (Q4 2025)

Gross profit for Q4 was $237.7M (up 94.7% y/y) with consolidated gross margin expanding. Adjusted EBITDA improved to $12.9M in Q4 (versus a negative in prior year). GAAP net loss for Q4 was $(54.2)M, which included $48.7M of stock‑based compensation and related employer payroll taxes; full‑year net loss was $(245.0)M including $136.3M of stock comp.

Balance sheet and contract metrics (Q4 2025)

As of December 31, 2025 Tempus reported approximately $759.7M in cash and marketable securities, Total Remaining Contract Value of over $1.1B, and Net Revenue Retention of 126%.

Guidance (2026)

Tempus provided 2026 guidance of roughly $1.59B in revenue and expects full‑year 2026 Adjusted EBITDA of approximately $65M, signaling management’s focus on scaling revenue while driving toward positive operating cash flow and profitability.

Recent operational highlights

Key non‑financial developments cited: launch of Paige Predict (AI digital pathology), study results for the AI‑driven Immune Profile Score showing improved immunotherapy prediction, a multi‑year collaboration with NYU Langone Health for serial molecular profiling, and selection by Northwestern Medicine to expand genomic testing access.